Table 4. Comparison of responders (reduction in seizure frequency of ≥50%) and nonresponders.

	Responders (n=28)	Nonresponders (n=53)	p
Sex, female	18 (64.3)	19 (35.8)	0.015
Age, years	17 (27, 12, 14–20)	17 (32, 12, 14–20)	0.226
Age at onset of seizures, years	2 (11, 0, 1–4)	5 (15, 0, 2–10)	0.002
Adolescents* (n=53)	21 (75.0)	32 (60.4)	0.188
Body weight, kg	52.3±15.5	55.2±21.2	0.517
Type of seizures
Focal to bilateral tonic-clonic seizures	16 (57.1)	32 (60.4)	0.778
Others	5 (17.9)	7 (13.2)	0.743
Cognitive impairment (n=67)	23/24 (95.8)	34/43 (79.1)	0.082
Concomitant AEDs	3 (5, 1, 2–4)	4 (6, 2, 3–5)	0.005
Concomitant use of CBZ, PHT, or OXC	7 (25.0)	13 (24.5)	0.963
Seizure frequency per month
Baseline	10 (900, 1, 5–70)	30 (300, 1, 5–101)	0.618
After 3 months	1 (300, 0, 0–10)	27 (300, 0, 7–90)	<0.001
Maximum dose of perampanel, mg	9 (12, 4, 8–10)	8 (12, 2, 6–12)	0.945

Data are median (maximum, minimum, interquartile range), mean±standard-deviation, or n (%) values.

^*Up to 18 years old.

AED: antiepileptic drug, CBZ: carbamazepine, OXC: oxcarbazepine, PHT: phenytoin.